Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
100 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2016 Summary
Global Markets Direct's, 'Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2016', provides an overview of the Peripheral Neuropathy (Sensory Neuropathy) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Peripheral Neuropathy (Sensory Neuropathy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peripheral Neuropathy (Sensory Neuropathy) and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Peripheral Neuropathy (Sensory Neuropathy) - The report reviews pipeline therapeutics for Peripheral Neuropathy (Sensory Neuropathy) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Peripheral Neuropathy (Sensory Neuropathy) therapeutics and enlists all their major and minor projects - The report assesses Peripheral Neuropathy (Sensory Neuropathy) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Peripheral Neuropathy (Sensory Neuropathy) Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Peripheral Neuropathy (Sensory Neuropathy) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Peripheral Neuropathy (Sensory Neuropathy) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Peripheral Neuropathy (Sensory Neuropathy) Overview 9 Therapeutics Development 10 Pipeline Products for Peripheral Neuropathy (Sensory Neuropathy) - Overview 10 Pipeline Products for Peripheral Neuropathy (Sensory Neuropathy) - Comparative Analysis 11 Peripheral Neuropathy (Sensory Neuropathy) - Therapeutics under Development by Companies 12 Peripheral Neuropathy (Sensory Neuropathy) - Therapeutics under Investigation by Universities/Institutes 14 Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Unknown Stage Products 18 Peripheral Neuropathy (Sensory Neuropathy) - Products under Development by Companies 19 Peripheral Neuropathy (Sensory Neuropathy) - Products under Investigation by Universities/Institutes 20 Peripheral Neuropathy (Sensory Neuropathy) - Companies Involved in Therapeutics Development 21 Araim Pharmaceuticals, Inc. 21 Arcturus Therapeutics, Inc 22 aTyr Pharma, Inc. 23 Baxalta Incorporated 24 CSL Limited 25 GeNeuro SA 26 INSYS Therapeutics, Inc. 27 Mitsubishi Tanabe Pharma Corporation 28 Neuren Pharmaceuticals Limited 29 Neurocentrx Pharma Ltd. 30 Pfizer Inc. 31 Polyneuron Pharmaceuticals AG 32 RegeneRx Biopharmaceuticals, Inc. 33 Sanofi 34 Teijin Pharma Limited 35 Peripheral Neuropathy (Sensory Neuropathy) - Therapeutics Assessment 36 Assessment by Monotherapy Products 36 Assessment by Combination Products 37 Assessment by Target 38 Assessment by Mechanism of Action 40 Assessment by Route of Administration 42 Assessment by Molecule Type 44 Drug Profiles 46 (immune globulin (human) + hyaluronidase (recombinant)) - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 aminoquinol - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Cannabidiol - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 cibinetide - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Drugs for Peripheral Neuropathy - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 fingolimod hydrochloride - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 GL-2045 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 GNbAC-1 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 immune globulin (human) - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 immune globulin (human) - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 immune globulin (human) - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 LUNAR-102 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 NNZ-2591 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 Peptide to Activate GLP1R for CNS, Metabolic Disorders and Head Trauma - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 Peptides to Activate GLP-1 Receptor for CNS Disorders and Head Trauma - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 pirenzepine hydrochloride - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 PN-1007 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 Proteins for Inflammation, Hematological, Metabolic, Oncology, Neurodegenerative and Cardiovascular Disorder - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 RGN-352 - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 SAR-184841 - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 Synthetic Peptides for Peripheral Neuropathy - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 Peripheral Neuropathy (Sensory Neuropathy) - Recent Pipeline Updates 78 Peripheral Neuropathy (Sensory Neuropathy) - Dormant Projects 91 Peripheral Neuropathy (Sensory Neuropathy) - Discontinued Products 93 Peripheral Neuropathy (Sensory Neuropathy) - Product Development Milestones 94 Featured News & Press Releases 94 Aug 10, 2015: Gliknik Licensee Pfizer Receives Orphan Drug Designation From U.S. Food and Drug Administration for Drug Candidate Directed Towards Rare Neurological Disorder 94 Jul 12, 2013: Neuren Receives Notice of Allowance for New Patent 94 Apr 04, 2013: CSL Behring's Privigen Obtains European Approval For Treatment Of Chronic Inflammatory Demyelinating Polyneuropathy 94 Feb 21, 2013: CHMP Adopts Positive Opinion Recommending Variation To Terms Of Marketing Authorization For CSL Behring's Privigen 95 Jun 27, 2012: PRIMA Study Shows Treatment With Privigen Improved Function In Patients With Chronic Inflammatory Demyelinating Polyneuropathy 96 May 30, 2012: CSL Behring Submits Marketing Authorization Variation Application To EMA For Privigen In Chronic Inflammatory Demyelinating Polyradiculoneuropathy 97 Mar 26, 2012: CSL Behring Enrolls First Patient In PATH Trial To Evaluate Hizentra For Treatment Of CIDP 97 Appendix 99 Methodology 99 Coverage 99 Secondary Research 99 Primary Research 99 Expert Panel Validation 99 Contact Us 99 Disclaimer 100
List of Tables
Number of Products under Development for Peripheral Neuropathy (Sensory Neuropathy), H1 2016 10 Number of Products under Development for Peripheral Neuropathy (Sensory Neuropathy) - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 13 Number of Products under Investigation by Universities/Institutes, H1 2016 14 Comparative Analysis by Late Stage Development, H1 2016 15 Comparative Analysis by Clinical Stage Development, H1 2016 16 Comparative Analysis by Early Stage Development, H1 2016 17 Comparative Analysis by Unknown Stage Development, H1 2016 18 Products under Development by Companies, H1 2016 19 Products under Investigation by Universities/Institutes, H1 2016 20 Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Araim Pharmaceuticals, Inc., H1 2016 21 Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Arcturus Therapeutics, Inc, H1 2016 22 Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by aTyr Pharma, Inc., H1 2016 23 Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Baxalta Incorporated, H1 2016 24 Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by CSL Limited, H1 2016 25 Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by GeNeuro SA, H1 2016 26 Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by INSYS Therapeutics, Inc., H1 2016 27 Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016 28 Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Neuren Pharmaceuticals Limited, H1 2016 29 Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Neurocentrx Pharma Ltd., H1 2016 30 Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Pfizer Inc., H1 2016 31 Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Polyneuron Pharmaceuticals AG, H1 2016 32 Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2016 33 Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Sanofi, H1 2016 34 Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Teijin Pharma Limited, H1 2016 35 Assessment by Monotherapy Products, H1 2016 36 Assessment by Combination Products, H1 2016 37 Number of Products by Stage and Target, H1 2016 39 Number of Products by Stage and Mechanism of Action, H1 2016 41 Number of Products by Stage and Route of Administration, H1 2016 43 Number of Products by Stage and Molecule Type, H1 2016 45 Peripheral Neuropathy (Sensory Neuropathy) Therapeutics - Recent Pipeline Updates, H1 2016 78 Peripheral Neuropathy (Sensory Neuropathy) - Dormant Projects, H1 2016 91 Peripheral Neuropathy (Sensory Neuropathy) - Dormant Projects (Contd..1), H1 2016 92 Peripheral Neuropathy (Sensory Neuropathy) - Discontinued Products, H1 2016 93
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.